ALPHATEC HOLDINGS, INC. (NASDAQ:ATEC) Files An 8-K Results of Operations and Financial Condition
Item 2.02

Results of Operations and Financial Condition

On January 7, 2019, Alphatec Holdings, Inc. (the “Company”) issued a press release announcing selected preliminary unaudited financial information for the quarter and full year ended December 31, 2018 (the “Press Release”).The Company has not finalized its financial statement closing process for the fourth quarter or full year ended December 31, 2018.As a result, the information in the Press Release is preliminary and based upon information available to the Company as of the date of the Press Release.During the course of the Company’s closing process, items may be identified that would require the Company to make adjustments, which may be material, and as a result, the estimates included in the Press Release are subject to risks and uncertainties, including possible adjustments to preliminary operating results.

A copy of the Press Release is attached to this Form 8-K as Exhibit 99.1.The information being furnished in this Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

In the Press Release, the Company also announced that, on December 31, 2018, Terry Rich entered into a Resignation and Transition Agreement (the “Resignation Agreement”) with the Company and its wholly owned subsidiary Alphatec Spine Inc. (“Spine”) (collectively, the “Companies”), to which Mr.Rich resigned, effective as of December 31, 2018, as the Companies’ President and Chief Operating Officer.Mr. Rich also resigned, effective December 31, 2018, as a director of the Companies. Mr.Rich’s resignation was not the result of any disagreements with the Companies, their respective Boards of Directors or their management in any matters relating to operations, policies or practices.

to the Resignation Agreement, Mr.Rich will provide consulting services to the Companies through June30, 2019 (the “Consulting Term”). Mr.Rich will receive consulting consideration comprised of seventy-five thousand (75,000) restricted shares of the Company’s common stock, granted within five (5) days of his execution of the Resignation Agreement, and payment of one hundred thousand dollars ($100,000) within five (5) days after completion of the Consulting Term.The payment of the consulting consideration shall be conditioned on Mr.Rich’s satisfactory completion of the specified consulting services.The Resignation Agreement also contains certain restrictive covenants and confidentiality provisions, including non-solicitation and non-disparagement obligations.

In connection with entrance into the Resignation Agreement, on December 31, 2018, Mr. Rich also entered into a Separation and Release Agreement (the “Separation Agreement”) with the Companies. to the Separation Agreement, and in consideration for his execution of a release and waiver agreement in favor of the Companies related to any claims or potential claims, Mr.Rich is entitled to receive a cash payment of three hundred thousand dollars ($300,000) within five (5) days after the effective date of the Separation Agreement (as defined therein), less applicable withholding amounts. In addition, the Company will pay the cost of COBRA insurance coverage for Mr.Rich and his eligible family members through the earlier of June 30, 2020, or the time at which he obtains alternate insurance coverage, and provide up to ten thousand dollars ($10,000) for executive resume and employment transition services.As additional consideration, Mr.Rich’s granted equity shall continue to vest during the Consulting Term and, following the Consulting Term, his outstanding, vested stock options will be converted into non-qualified stock options and remain exercisable until each such option’s respective expiration date. The Separation Agreement also contains certain restrictive covenants and confidentiality provisions, including non-solicitation and non-disparagement obligations.

The foregoing descriptions of the Resignation Agreement and the Separation Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, a copy of which will be filed with the Company’s Annual Report on Form10-K for the period ending December 31, 2018.

Alphatec Holdings, Inc. Exhibit
EX-99.1 2 atec-ex991_6.htm EX-99.1 atec-ex991_6.htm Exhibit 99.1 Alphatec Announces 2018 Preliminary Revenue Results,…
To view the full exhibit click here

About ALPHATEC HOLDINGS, INC. (NASDAQ:ATEC)

Alphatec Holdings, Inc. is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc. and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures. Its products include Cervical and Cervico-Thoracic Products, which include Trestle Luxe Anterior Cervical Plate System and Pegasus Anchored Cervical Interbody; Thoracolumbar Fixation Products, which include Arsenal Degenerative System and OsseoScrew Spinal Fixation System; Spinal Spacers, which include Battalion Universal Spacer System and Alphatec Solus Locking ALIF Spinal Spacer; minimally invasive surgery Products, which include Illico Minimally Invasive Surgery System and BridgePoint Spinous Process Fixation System, and Biologics, which include Neocore Osteoconductive Matrix.